EVALUATING THE LONG-TERM IMPACT OF IMPROVING CARE FOR PATIENTS WITH TYPE 2 DIABETES IN CHINAVALUE IN HEALTHIF62017-10-010OAAI
QUANTIFYING THE TRADE-OFF BETWEEN IMPROVED GLYCEMIC CONTROL AND SEVERE HYPOGLYCEMIA RISK IN PATIENTS WITH TYPE 1 DIABETES: A HEALTH ECONOMIC ANALYSIS IN THE UKVALUE IN HEALTHIF62017-10-010OAAI
EVALUATING THE COST-EFFECTIVENESS OF LIRAGLUTIDE 1.8MG VERSUS LIXISENATIDE 20μG FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE SPANISH SETTINGVALUE IN HEALTHIF62016-11-010OAAI
PROJECTED LONG-TERM OUTCOMES IN PATIENTS WITH TYPE 1 DIABETES MELLITUS TREATED WITH FASTER-ACTING INSULIN ASPART VERSUS CONVENTIONAL INSULIN ASPART IN THE UK SETTINGVALUE IN HEALTHIF62016-11-010OAAI
SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITIES FOR ADULTS WITH TYPE 1 DIABETESVALUE IN HEALTHIF62015-11-010OAAI
COST-EFFECTIVENESS OF RAPID-ACTING ANALOG INSULIN FOR TYPE 1 DIABETES IN THE UK SETTINGVALUE IN HEALTHIF62015-11-011OAAI
EVALUATING THE COST-EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UKVALUE IN HEALTHIF62015-11-011OAAI
ESTIMATING THE LONG-TERM CLINICAL AND ECONOMIC BENEFITS OF INSULIN LISPRO INTYPE I DIABETES IN THE UNITED KINGDOM: A COST-EFFECTIVENESS ANALYSIS BASED ON THE RESULTS OF A RECENT META-ANALYSISVALUE IN HEALTHIF62008-11-010OAAI
HEALTH ECONOMIC ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED TO MULTIPLE DAILY INJECTIONS FOR THE TREATMENT OF TYPE I DIABETES IN POLANDVALUE IN HEALTHIF62008-11-012OAAI
Long-term clinical and cost outcomes of treatment with insulin detemir plus insulin aspart in type 1 diabetes patients in the Czech setting; Data from the predictive studyVALUE IN HEALTHIF62008-05-010OAAI
Canadian cost utility analysis comparing exenatide versus insulin glargine in patients with type two diabetesVALUE IN HEALTHIF62008-05-010OAAI
Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in ChinaVALUE IN HEALTHIF62007-11-010OAAI
Long-term cost-effectiveness analysis of a modern insulin in patients with poorly controlled type 2 diabetes in the german setting; Data from the predictive studyVALUE IN HEALTHIF62007-11-010OAAI
Cost-effectiveness of detemir versus NPH for type I diabetes patients treated with basal-bolus therapy in a Belgium setting. A modeling evaluation based on results from a meta-analysis of three clinical trialsVALUE IN HEALTHIF62007-11-010OAAI
Cost-utility of insulin detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in a French setting. A modeling evaluation based on results from a meta-analysis of three clinical trialsVALUE IN HEALTHIF62007-11-010OAAI
Evaluating the long-term clinical and economic implications of converting type 2 diabetes patients to insulin detemir (±oral hypoglycemic agents) from insulin glargine based regimens in Germany;: Data from the predictive studyVALUE IN HEALTHIF62007-11-011OAAI
Cost-effectiveness of insulin detemir versus NPH for type I diabetes patients in a German setting. A modeling evaluation based upon results from a meta-analysisVALUE IN HEALTHIF62007-11-010OAAI
Mealtime insulin aspart reduces the long-term cost of complications compared to human insulin as part of basal-bolus therapy in polish type 2 diabetes patientsVALUE IN HEALTHIF62007-11-010OAAI
Long-term cost-utility analysis of insulin aspart (Novorapid®) versus human soluble insulin in type 2 diabetes patients in the German settingVALUE IN HEALTHIF62007-11-010OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向